Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Purpose

The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objective of the study is to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse.

Condition

  • Ovarian Cancer

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically or cytologically confirmed high grade serous or high grade endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer that is recurrent. - Participants whose tumor carries germline or somatic deleterious or suspected deleterious mutations in the genes BRCA1 (Breast Cancer gene 1) and BRCA2 (Breast Cancer gene 2), and/or tumors with positive HRD status. The presence of any of these mutations and/or the homologous recombination deficiency (HRD) status will be determined according to routinely used local standard of care tests. Results must be available before screening. - Radiologically confirmed/documented disease progression while on Poly (ADP-ribose) polymerase (PARP) inhibitors therapy in either first or second-line maintenance setting (only 1 line of PARPi maintenance is allowed with or without bevacizumab). Note: Documentation of disease progression must be within 28 days of last PARPi dose taken. Surgical salvage intervention and/or focal ablative therapies are allowed, (further disease progression after these interventions must be documented), AND Clinically benefited from PARPi maintenance prior to documented progression, as defined by at least 6 months of treatment duration with no progressive disease observed, AND either, Progression on first-line maintenance PARPi: Participants are allowed maximum 1 additional line of platinum-based chemotherapy before study entry. (note: treatment-free interval on platinum rechallenge must be >6 months, with documented disease progression prior to study entry). OR Progression on second-line maintenance PARPi: Participants are not allowed any additional systemic anticancer treatments before study entry (that is PARPi is the last treatment before study entry) - Measurable disease per RECIST v1.1, as assessed by Investigator. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 6 months. - Other Protocol defined inclusion criteria could apply.

Exclusion Criteria

  • Primary platinum-refractory disease defined as disease progression during primary platinum-based chemotherapy or platinum-resistant disease defined as disease progression within 6 months of the last platinum administration in the second-line setting. - History of additional malignancy within 3 years before the date of enrollment. - Known brain metastases, unless clinically stable, that is without evidence of progression by imaging for at least 4 weeks prior to the first dose of study intervention, no evidence of new brain metastases, and on a stable or decreasing dose of ≤ 10 mg of prednisone (or equivalent) or without corticosteroids for at least 14 days prior to study intervention administration. - Active and/or uncontrolled infection. - History of known hypersensitivity to the active substances or to any excipients (e.g. polysorbate 80) of the study interventions. - Organ transplantation, including allogenic stem cell transplant. - Other Protocol defined exclusion criteria could apply.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Tuvusertib with Niraparib
  • Drug: Tuvusertib (M1774)
    Tuvusertib will be administered orally
    Other names:
    • M1774, VXc-400, VRT-1363004, substance code MSC2584415A
  • Drug: Niraparib
    Niraparib will be administered orally
    Other names:
    • GSK3985771, MK-4827
Experimental
Tuvusertib with Lartesertib
  • Drug: Tuvusertib (M1774)
    Tuvusertib will be administered orally
    Other names:
    • M1774, VXc-400, VRT-1363004, substance code MSC2584415A
  • Drug: Lartesertib (M4076)
    Lartesertib will be administered orally
    Other names:
    • M4076, substance code MSC2585823A

Recruiting Locations

Istituto Oncologico della Svizzera Italiana (IOSI)- Ente Ospedaliero Cantonale (EOC) - Ospedale S.Giovann
Little Rock, Arkansas 72205
Contact:
Michael Birrer
mjbirrer@uams.edu

Centricity Research Cancer Center - DBA CRRI John B. Amos Cancer Center Research
Columbus, Georgia 31904
Contact:
greg.sfakianos@centricityresearch.com

Next Oncology - Virginia
Fairfax, Virginia 22031

More Details

NCT ID
NCT06433219
Status
Recruiting
Sponsor
EMD Serono Research & Development Institute, Inc.

Study Contact

US Medical Information
888-275-7376
eMediUSA@emdserono.com